Atrial Fibrillation
Friday, May 17th, 2013
Future Medicine: May 13, 2013 Aim: To assess, through a systematic review, evidence for the effects of antiarrhythmic drugs (AADs) on cardiovascular (CV) hospitalization and mortality.Materials & methods: English language articles were identified using MEDLINE, EMBASE and the Cochrane Clinical Trial Registry and were screened for study applicability and methodological quality. Results: Out of 3526 identified studies, 38 were […]
Atrial Fibrillation
Friday, May 17th, 2013
J Am Coll Cardiology: May 1, 2013 Objective s: To evaluate the results associated with left atrial appendage closure (LAAC) with the Amplatzer Cardiac Plug (ACP) in patients with non-valvular atrial fibrillation (NVAF) and absolute contraindication for anticoagulation therapy. Background Little data exist on the late outcomes following LAAC in patients with absolute contraindication for warfarin. Read […]
Clinical Trials
Friday, May 17th, 2013
STROKEAHA: May 14, 2013 Background and Purpose—Atrial fibrillation (AF) is the most frequent risk factor in ischemic stroke but often remains undetected. We analyzed the value of insertable cardiac event recorder in detection of AF in a 1-year cohort of patients with cryptogenic ischemic stroke. Read more
Clinical Trials
Friday, May 17th, 2013
STROKEAHA: May 14, 2013 Background and Purpose—To provide evidence whether mechanical thrombectomy with stent-retrievers in the treatment of acute ischemic stroke causes intimal damage. Methods—This study analyzed thrombi retrieved by mechanical thrombectomy from cerebral arteries in 48 consecutive patients with acute ischemic stroke for the presence of endothelial cells using CD34 antibodies. Read more
Clinical Trials
Friday, May 17th, 2013
JAMA Intern Medicine: May 13, 2013 Prior studies have shown that 25% to 50% of clinical trials are never published.1– 4 However, among those published, we know little about the length of time required for publication in the peer-reviewed biomedical literature after study completion. Ioannidis5 previously demonstrated that a sample of randomized phase 2 and 3 trials conducted between […]
Clinical Trials
Friday, May 17th, 2013
STROKEAHA: May 9, 2013 Background and Purpose—Two randomized trials suggested that transcranial laser therapy (TLT) may benefit patients with acute ischemic stroke, although efficacy has not been confirmed. Supportive proof of concept could be demonstrated if TLT reduces the volume of cortical infarction. Methods—The NeuroThera Efficacy and Safety Trial-2 (NEST-2) was a randomized trial of TLT […]
Clinical Trials
Friday, May 17th, 2013
STROKEAHA: May 9, 2013 Background and Purpose—High blood pressure is common in the acute phase of stroke and is associated with poor outcome. We examined whether blood pressure–lowering treatment with candesartan in the acute phase affects long-term cognitive function and quality of life. Methods—Scandinavian Candesartan Acute Stroke Trial was a randomized-controlled and placebo-controlled trial of candesartan […]
Therapies
Friday, May 17th, 2013
STROKEAHA: May 14, 2013 Background and Purpose—Sex and race reportedly influence outcome after recombinant tissue-type plasminogen activator (rtPA). It is, however, unclear whether baseline imbalances (eg, stroke severity) or lack of response to thrombolysis is responsible. We applied balancing methods to test the hypothesis that race and sex influence outcome after rtPA independent of baseline […]
Therapies
Friday, May 17th, 2013
Circulation: May 14, 2013 Background—Onset-to-reperfusion time has been reported to be associated with clinical prognosis. However, its impact on mortality remained to be assessed. Using a collaborative pooled analysis, we examined whether early mortality after successful endovascular treatment is time dependent. Methods and Results—In a collaborative pooled analysis of 7 endovascular databases, we assessed the impact […]
Therapies
Friday, May 17th, 2013
JAMA Neurology: May 13, 2013 Importance Studies comparing the efficacy of intra-arterial therapy (IAT) and medical therapy in reducing final infarct volume (FIV) in intracranial large-vessel occlusions (ILVOs) are lacking. Objectives To assess whether patients with ILVOs who received IAT have smaller FIVs than patients who received either intravenous tissue plasminogen activator therapy (IVT) or no reperfusion therapy […]
